Tier 2 — strong

The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial

Joshua J Broman-Fulks, Will H Canu, Krystal L Trout, David C Nieman
Therapeutic advances in psychopharmacology 2012 2(4):131

Bibliography

PubMed
PMID 23983966
PubMed Central
PMC3736941
DOI
10.1177/2045125312445894
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: statement: D.C. Nieman is a board member of Quercegen Pharma. The other authors have no conflict of interest.

Study snapshot

DesignRandomized placebo-controlled community cognition trial
ModelHuman intervention research
Sample941 adults
InterventionQuercetin 500 or 1,000 mg/day or placebo
Duration12 weeks
EndpointsExposure and pharmacokinetics; Cognitive, mood, or sleep measures

What the study showed, in plain terms

Published in 2012, this source examined brain, cognition and sleep. Design: Randomized placebo-controlled community cognition trial. Sample/model: 941 adults. The exposure or intervention was Quercetin 500 or 1,000 mg/day or placebo. Follow-up or treatment period: 12 weeks.

Memory, attention, reaction time, psychomotor speed, and cognitive flexibility did not improve despite higher plasma quercetin.

An outcome report from the same large community supplementation program; it should not be counted as an independent cohort from related reports.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Memory, attention, reaction time, psychomotor speed, and cognitive flexibility did not improve despite higher plasma quercetin.
  • The recorded outcome domains were Exposure and pharmacokinetics; Cognitive, mood, or sleep measures.
  • The result applies to the tested exposure: Quercetin 500 or 1,000 mg/day or placebo; 12 weeks.

What this study can and cannot tell us

  • An outcome report from the same large community supplementation program; it should not be counted as an independent cohort from related reports.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Influence of quercetin supplementation on disease risk factors in community-dwelling adults
Amy M Knab et al. · Journal of the American Dietetic Association · 2011
Tier 2
Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial
Serena A Heinz et al. · Pharmacological research · 2010
Tier 2
The variable plasma quercetin response to 12-week quercetin supplementation in humans
F Jin et al. · European journal of clinical nutrition · 2010
Tier 2
Quercetin with vitamin C and niacin does not affect body mass or composition
Amy M Knab et al. · Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2011
Tier 2
A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects
Serena A Heinz et al. · The British journal of nutrition · 2010
Tier 2
Dose-response to 3 months of quercetin-containing supplements on metabolite and quercetin conjugate profile in adults
Lynn Cialdella-Kam et al. · The British journal of nutrition · 2013

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology